{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:44:50Z","timestamp":1788561890261,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real-world data have shown mild improvement of overall motor function in adult patients treated with nusinersen, the first approved therapy for 5q-spinal muscular atrophy (SMA). However, knowledge about preferably targeted muscle functions is sparse. The aim of this study was to evaluate strength of distinct muscles and body regions in adult SMA patients in the early course of nusinersen therapy. 72 muscles of 15 patients were tested on the Medical Research Council (MRC) 0\u201310 scale (translated into MRC %) from nusinersen start to 14\u00a0months of treatment. The whole body muscular strength improved slightly or remained stable in 80% of SMA patients with a median improvement of\u2009+\u20092%. However, relevant increases of muscle strength of distinct regions were identified in the proximal upper limbs and shoulder girdle (median\u2009+\u20098%) and in muscle groups with a preserved function pre-treatment, even in more advanced diseased SMA patients. MRC grading was additionally performed in seven patients enrolled during ongoing treatment. Here, further improvement of muscle strength until month 18\u201326 was seen with the highest increases in the proximal upper and lower limbs. Our findings suggest that sole evaluation of the overall muscle strength might underestimate nusinersen therapy benefits.<\/jats:p>","DOI":"10.1038\/s41598-023-31617-5","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T10:12:23Z","timestamp":1681726343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Improvement of muscle strength in specific muscular regions in nusinersen-treated adult patients with 5q-spinal muscular atrophy"],"prefix":"10.1038","volume":"13","author":[{"given":"Olivia","family":"Schreiber-Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Alexandra","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Wieselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Kumpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gresa","family":"Ranxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-8423","authenticated-orcid":false,"given":"Alma","family":"Osmanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"31617_CR1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/s0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn, M. R. & Wang, C. H. Spinal muscular atrophy. Lancet 371, 2120\u20132133. https:\/\/doi.org\/10.1016\/s0140-6736(08)60921-6 (2008).","journal-title":"Lancet"},{"key":"31617_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy, S. M. Nusinersen: First global approval. Drugs 77, 473\u2013479. https:\/\/doi.org\/10.1007\/s40265-017-0711-7 (2017).","journal-title":"Drugs"},{"key":"31617_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752 (2017).","journal-title":"N. Engl. J. Med."},{"key":"31617_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625\u2013635. https:\/\/doi.org\/10.1056\/NEJMoa1710504 (2018).","journal-title":"N. Engl. J. Med."},{"key":"31617_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/s1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker, T. et al. Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study. Lancet Neurol. 19, 317\u2013325. https:\/\/doi.org\/10.1016\/s1474-4422(20)30037-5 (2020).","journal-title":"Lancet Neurol."},{"key":"31617_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi, L. et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J. Neurol. Neurosurg. Psychiatry 91, 1166\u20131174. https:\/\/doi.org\/10.1136\/jnnp-2020-323822 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"31617_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/jnd-190453","volume":"7","author":"CJJ Yeo","year":"2020","unstructured":"Yeo, C. J. J., Simeone, S. D., Townsend, E. L., Zhang, R. Z. & Swoboda, K. J. Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy. J. Neuromuscul. Dis. 7, 257\u2013268. https:\/\/doi.org\/10.3233\/jnd-190453 (2020).","journal-title":"J. Neuromuscul. Dis."},{"key":"31617_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/jnd-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter, M. C. et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J. Neuromuscul. Dis. 6, 453\u2013465. https:\/\/doi.org\/10.3233\/jnd-190416 (2019).","journal-title":"J. Neuromuscul. Dis."},{"key":"31617_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10223-9","author":"B De Wel","year":"2020","unstructured":"De Wel, B. et al. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. J. Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10223-9 (2020).","journal-title":"J. Neurol."},{"key":"31617_CR10","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1212\/wnl.0000000000009914","volume":"95","author":"O Moshe-Lilie","year":"2020","unstructured":"Moshe-Lilie, O. et al. Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center. Neurology 95, e413\u2013e416. https:\/\/doi.org\/10.1212\/wnl.0000000000009914 (2020).","journal-title":"Neurology"},{"key":"31617_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti, G. et al. Motor function in type 2 and 3 SMA patients treated with Nusinersen: A critical review and meta-analysis. Orphanet. J. Rare Dis. 16, 430. https:\/\/doi.org\/10.1186\/s13023-021-02065-z (2021).","journal-title":"Orphanet. J. Rare Dis."},{"key":"31617_CR12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00415-019-09646-w","volume":"267","author":"C Brogna","year":"2020","unstructured":"Brogna, C. et al. MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients. J. Neurol. 267, 898\u2013912. https:\/\/doi.org\/10.1007\/s00415-019-09646-w (2020).","journal-title":"J. Neurol."},{"key":"31617_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone, E. S. et al. Revised upper limb module for spinal muscular atrophy: Development of a new module. Muscle Nerve 55, 869\u2013874. https:\/\/doi.org\/10.1002\/mus.25430 (2017).","journal-title":"Muscle Nerve"},{"key":"31617_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O'Hagen","year":"2007","unstructured":"O\u2019Hagen, J. M. et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul. Disord. 17, 693\u2013697. https:\/\/doi.org\/10.1016\/j.nmd.2007.05.009 (2007).","journal-title":"Neuromuscul. Disord."},{"key":"31617_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman, A. M. et al. Validation of the expanded hammersmith functional motor scale in spinal muscular atrophy type II and III. J. Child Neurol. 26, 1499\u20131507. https:\/\/doi.org\/10.1177\/0883073811420294 (2011).","journal-title":"J. Child Neurol."},{"key":"31617_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera, M. C. et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 17, 39. https:\/\/doi.org\/10.1186\/s12883-017-0790-9 (2017).","journal-title":"BMC Neurol."},{"key":"31617_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw, S. et al. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 17, 68. https:\/\/doi.org\/10.1186\/s12883-017-0853-y (2017).","journal-title":"BMC Neurol."},{"key":"31617_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/jnd-200534","volume":"7","author":"VA Sansone","year":"2020","unstructured":"Sansone, V. A. et al. Measuring outcomes in adults with spinal muscular atrophy\u2014challenges and future directions\u2014meeting report. J. Neuromuscul. Dis. 7, 523\u2013534. https:\/\/doi.org\/10.3233\/jnd-200534 (2020).","journal-title":"J. Neuromuscul. Dis."},{"key":"31617_CR19","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Risdiplam: First approval. Drugs 80, 1853\u20131858. https:\/\/doi.org\/10.1007\/s40265-020-01410-z (2020).","journal-title":"Drugs"},{"key":"31617_CR20","doi-asserted-by":"publisher","first-page":"175628641880324","DOI":"10.1177\/1756286418803246","volume":"11","author":"B Stolte","year":"2018","unstructured":"Stolte, B. et al. Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy. Ther. Adv. Neurol. Disord. 11, 1756286418803246. https:\/\/doi.org\/10.1177\/1756286418803246 (2018).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"31617_CR21","doi-asserted-by":"publisher","unstructured":"Montes, J. et al. Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PloS One 13, e0199657. https:\/\/doi.org\/10.1371\/journal.pone.0199657 (2018).","DOI":"10.1371\/journal.pone.0199657"},{"key":"31617_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1212\/01.wnl.0000324623.89105.c4","volume":"71","author":"F Deymeer","year":"2008","unstructured":"Deymeer, F., Serdaroglu, P., Parman, Y. & Poda, M. Natural history of SMA IIIb: Muscle strength decreases in a predictable sequence and magnitude. Neurology 71, 644\u2013649. https:\/\/doi.org\/10.1212\/01.wnl.0000324623.89105.c4 (2008).","journal-title":"Neurology"},{"key":"31617_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.nmd.2012.06.352","volume":"22","author":"U Werlauff","year":"2012","unstructured":"Werlauff, U., Vissing, J. & Steffensen, B. F. Change in muscle strength over time in spinal muscular atrophy types II and III A long-term follow-up study. Neuromuscul. Disord. 22, 1069\u20131074. https:\/\/doi.org\/10.1016\/j.nmd.2012.06.352 (2012).","journal-title":"Neuromuscul. Disord."},{"key":"31617_CR24","doi-asserted-by":"publisher","unstructured":"Carter, G. T. et al. Profiles of neuromuscular diseases. Spinal muscular atrophy. Am. J. Phys. Med. Rehabil. 74, S150\u2013159. https:\/\/doi.org\/10.1097\/00002060-199509001-00009 (1995).","DOI":"10.1097\/00002060-199509001-00009"},{"key":"31617_CR25","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","volume":"255","author":"S Piepers","year":"2008","unstructured":"Piepers, S. et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J. Neurol. 255, 1400\u20131404. https:\/\/doi.org\/10.1007\/s00415-008-0929-0 (2008).","journal-title":"J. Neurol."},{"key":"31617_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman, R. I. et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur. J. Neurol. 25, 512\u2013518. https:\/\/doi.org\/10.1111\/ene.13534 (2018).","journal-title":"Eur. J. Neurol."},{"key":"31617_CR27","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1212\/01.wnl.0000095961.66830.03","volume":"61","author":"Great Lakes ALS Study Group","year":"2003","unstructured":"Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 61, 1503\u20131507. https:\/\/doi.org\/10.1212\/01.wnl.0000095961.66830.03 (2003).","journal-title":"Neurology"},{"key":"31617_CR28","doi-asserted-by":"publisher","unstructured":"Florence, J. M. et al. Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys. Ther. 72, 115\u2013122. discussion 122\u2013116. https:\/\/doi.org\/10.1093\/ptj\/72.2.115 (1992).","DOI":"10.1093\/ptj\/72.2.115"},{"key":"31617_CR29","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/ptj\/67.9.1342","volume":"67","author":"CT Wadsworth","year":"1987","unstructured":"Wadsworth, C. T., Krishnan, R., Sear, M., Harrold, J. & Nielsen, D. H. Intrarater reliability of manual muscle testing and hand-held dynametric muscle testing. Phys. Ther. 67, 1342\u20131347. https:\/\/doi.org\/10.1093\/ptj\/67.9.1342 (1987).","journal-title":"Phys. Ther."},{"key":"31617_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/mus.880050405","volume":"5","author":"OM Scott","year":"1982","unstructured":"Scott, O. M., Hyde, S. A., Goddard, C. & Dubowitz, V. Quantitation of muscle function in children: A prospective study in Duchenne muscular dystrophy. Muscle Nerve 5, 291\u2013301. https:\/\/doi.org\/10.1002\/mus.880050405 (1982).","journal-title":"Muscle Nerve"},{"key":"31617_CR31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","volume":"367","author":"RJ Little","year":"2012","unstructured":"Little, R. J. et al. The prevention and treatment of missing data in clinical trials. N. Engl. J. Med. 367, 1355\u20131360. https:\/\/doi.org\/10.1056\/NEJMsr1203730 (2012).","journal-title":"N. Engl. J. Med."},{"key":"31617_CR32","doi-asserted-by":"publisher","unstructured":"Baschung Pfister, P. et al. Manual muscle testing and hand-held dynamometry in people with inflammatory myopathy: An intra- and interrater reliability and validity study. PloS one 13, e0194531. https:\/\/doi.org\/10.1371\/journal.pone.0194531 (2018).","DOI":"10.1371\/journal.pone.0194531"},{"key":"31617_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","volume":"17","author":"A Pechmann","year":"2022","unstructured":"Pechmann, A. et al. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study. Orphanet. J. Rare Dis. 17, 384. https:\/\/doi.org\/10.1186\/s13023-022-02547-8 (2022).","journal-title":"Orphanet. J. Rare Dis."},{"key":"31617_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","volume":"92","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam, D. et al. Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J. Neurol. Neurosurg. Psychiatry 92, 78\u201385. https:\/\/doi.org\/10.1136\/jnnp-2020-324254 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"31617_CR35","doi-asserted-by":"publisher","first-page":"175628642090780","DOI":"10.1177\/1756286420907803","volume":"13","author":"E Jochmann","year":"2020","unstructured":"Jochmann, E. et al. Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen. Ther. Adv. Neurol. Disord. 13, 1756286420907803. https:\/\/doi.org\/10.1177\/1756286420907803 (2020).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"31617_CR36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/brainsci11030367","volume":"11","author":"A Osmanovic","year":"2021","unstructured":"Osmanovic, A., Schreiber-Katz, O. & Petri, S. Nusinersen wearing-off in adult 5q-spinal muscular atrophy oatients. Brain Sci. 11, 367 (2021).","journal-title":"Brain Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31617-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31617-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31617-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T10:20:47Z","timestamp":1681726847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31617-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31617"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31617-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.S.-K. has received honoraria as a speaker\/consultant and\/or funding for travel expenses from the German Neuromuscular Society \u201cDeutsche Gesellschaft fuer Muskelkranke (DGM e.V.), Novartis, Biogen GmbH, Biermann Verlag GmbH, and MK\u2009+\u2009S\u2014Medizin, Kommunikation & Service GmbH. H.A.S. and G.W. report no conflicts of interest. M.K. and G.R. received travel cost compensations from Biogen GmbH. S.P. received honoraria as a speaker\/consultant from Biogen GmbH, Roche, Novartis, Teva, Cytoki-netics Inc., and Desitin; and grants from DGM e.V, Federal Ministry of Education and Research, German Israeli Foundation for Scientific Research and Development, EU Joint Programme for Neurodegenerative Disease Research. A.O. received honoraria as a speaker\/consultant from Biogen. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6240"}}